Airbnb Accused of Poaching Tour Guides From Rival Platforms to Grow Experiences
Whether the poaching attempts were a rogue or not, it's clear that Airbnb is going all-out to compete in its new experiences business.
Airbnb needs to expand its tour supply for its newly relaunched Experiences business, and two rival tour platforms say Airbnb tried to poach their guides.
Canada-headquartered ToursByLocals and Netherlands-based Withlocals said separately that people with Airbnb email addresses created accounts on their sites, and then violated their terms and conditions by messaging tour guides to recruit them to Airbnb Experiences.
'There's a better way to grow the travel experiences space and it's not by scraping platforms or poaching hosts," ToursByLocals CEO Lisa Chen said in a statement. "At ToursByLocals, our entire model is built around empowering local business
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
Is Net Worth More Important Than A High Salary? Some Say Yes, Others Argue A High Salary With Low Net Worth Is 'Much Easier To Fix'
When a Reddit user recently posted a rant claiming that net worth is more important than salary, it sparked a heated debate. The post criticized people who flaunt six-figure incomes but have little to show for it. The author questioned the value of a high paycheck if it all disappears to debt and lifestyle costs. 'Who cares what you make if you are still broke,' they wrote. The poster argued that plenty of six-figure earners live paycheck to paycheck and flex their income despite being buried in debt. 'I would rather make 50k a year and have 250k NW, than 150k a year and be in debt,' they wrote, adding, 'Having high NW displays financial discipline and competence.' Don't Miss: Maker of the $60,000 foldable home has 3 factory buildings, 600+ houses built, and big plans to solve housing — Peter Thiel turned $1,700 into $5 billion—now accredited investors are eyeing this software company with similar breakout potential. Learn how you can Some people agreed, pointing out that income is only one part of the story. 'I worked with a guy who made over 100k,' one commenter wrote. 'Refused to save anything, not even 401(k). He bought anything and everything he wanted. He's still doing it.' Others pushed back, saying a high salary gives you more options and flexibility. 'Give me the high salary and low net worth. Much easier to fix,' one person said. Another argued, 'That 150k [salary] can erase debt and build a 250k NW a hell of a lot faster than the 50k / 250k one can increase.' A more detailed reply laid out how someone earning $150,000 could contribute aggressively to retirement, get employer matches, and outpace someone with a smaller income within a few years. 'You could waste ALL of your 126.5K minus taxes and end up with a quarter mill in 5 years,' the commenter explained. Trending: Maximize saving for your retirement and cut down on taxes: . Despite disagreements, one consistent theme emerged: discipline matters more than raw numbers. 'If you have an uncontrollable spending problem, it doesn't matter how much you make,' a user wrote. 'You can make 1 million a year and if you still spend 1.2 million you're an idiot.' Another summed it up this way: 'Net worth isn't always a sign of discipline but your post is well taken. If I made a million dollars per year for one year it doesn't make you rich.' Several pointed out that net worth often includes illiquid assets like homes, which can inflate the numbers without improving someone's day-to-day finances. 'You can't access your 401(k) without paying a penalty... unless your net worth is mostly comprised of cash in a mattress, a low salary and high net worth won't increase your buying power,' one user the end, some people argued that the best position is to have both: a strong income and disciplined saving habits. Consistent contributions to your retirement—while increasing the percentage over time— and positive cash flow are even more important, as those will build your net worth over time. A high income can fuel savings and investment, while net worth provides security when income slows down. Building both and understanding how they support each other is what creates lasting financial stability. Read Next: Up Next: Transform your trading with Benzinga Edge's one-of-a-kind market trade ideas and tools. Click now to access unique insights that can set you ahead in today's competitive market. Get the latest stock analysis from Benzinga? APPLE (AAPL): Free Stock Analysis Report TESLA (TSLA): Free Stock Analysis Report This article Is Net Worth More Important Than A High Salary? Some Say Yes, Others Argue A High Salary With Low Net Worth Is 'Much Easier To Fix' originally appeared on © 2025 Benzinga does not provide investment advice. All rights reserved. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
2 hours ago
- Yahoo
2 Biotech Stocks to Buy Before They Soar 84% and 240%, According to Certain Wall Street Analysts
These biotech companies have several catalysts ahead -- and in the past have soared on good news. They both offer innovative candidates that could result in game-changing treatments for patients. 10 stocks we like better than Viking Therapeutics › If you're looking to add growth to your portfolio, biotech stocks can be a great choice. Exciting research is happening in these companies' labs, and in some cases, game-changing treatment candidates are approaching important milestones or even going over the finish line. As an investor in these companies, you can benefit as they report positive clinical trial news, score a regulatory approval, or start generating product revenue. Wall Street considers two candidates extremely compelling right now, with forecasts for potential gains of more than 80% and 200% in the coming 12 months. One of these players is working in the high-growth area of weight loss drugs, and the other candidate showed its strengths by winning the world's first-ever approval of a product based on CRISPR gene editing. Let's check out these two biotech stocks to buy before they skyrocket. Viking Therapeutics (NASDAQ: VKTX) soared early last year when it reported strong data from the phase 2 trial of its weight loss candidate, VK2735, but the stock has since given back those gains and is trading closer to the level it was at prior to that data announcement. Since, the company has continued to advance VK2735 in injectable form and a version in pill form, and demand for these sorts of drugs remains high -- these are two reasons to believe that Viking has the potential to take off again. And catalysts may be on the horizon. The drug works in a manner similar to Eli Lilly's blockbuster tirzepatide, sold under the names Mounjaro and Zepbound. These drugs interact with hormones involved in digestion and have helped people quickly and safely lose weight. Viking is beginning the phase 3 trial for injectable VK2735 in the second quarter and expects data from its phase 2 trial of the pill version in the second half. Any data announcements could result in big moves for the stock, as there is plenty of room for a new company to enter the weight loss drug market -- one forecast to approach $100 billion in a few years. Wall Street is optimistic about Viking's prospects, with the average price forecast predicting an increase of about 240% in the stock price from today's level. Of course, Viking depends heavily on the outcome of these trials, so some risk is involved -- but data have been strong, so growth investors may want to get in on Viking now to potentially post a big win later. CRISPR Therapeutics (NASDAQ: CRSP) stock surged in the year leading up to a major milestone: its first product approval. But since last year's launch of Casgevy, a gene-editing treatment for blood disorders, the stock has been on the decline. Sometimes, investors buy a stock well before the company wins approval or launches a product, then lock in gains after the good news lands -- and I think this is what's happened here. But what this does is offer us a chance to get in at a very good price on a promising company that could deliver fantastic news down the road. Casgevy, as a gene-editing treatment, requires a longer time to roll out than a pill or injection, as it includes several steps that happen over a period of months. The company recently said new patient initiations should increase "significantly" this year -- so there's reason to be optimistic about revenue growth ahead. CRISPR Therapeutics also recently reported positive phase 1 data for a gene editing candidate addressing the problem of high cholesterol. And the company expects to report data soon from a phase 1 trial of a candidate targeting patients with elevated levels of lipoprotein(a) -- a risk factor for cardiovascular events. These could represent huge markets for CRISPR Therapeutics if the candidates reach the finish line, and in the meantime, any potential positive news could boost the stock. The company also expects other trial updates in candidates for oncology and autoimmune diseases this year -- so this biotech's calendar is full of possible catalysts. Wall Street's average price forecast calls for an 84% gain for CRISPR Therapeutics from today's price -- if all goes well in clinical trials and Casgevy starts to show revenue growth, now could represent a golden buying opportunity for growth investors. Before you buy stock in Viking Therapeutics, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Viking Therapeutics wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $664,089!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $881,731!* Now, it's worth noting Stock Advisor's total average return is 994% — a market-crushing outperformance compared to 172% for the S&P 500. Don't miss out on the latest top 10 list, available when you join . See the 10 stocks » *Stock Advisor returns as of June 9, 2025 Adria Cimino has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends CRISPR Therapeutics. The Motley Fool recommends Viking Therapeutics. The Motley Fool has a disclosure policy. 2 Biotech Stocks to Buy Before They Soar 84% and 240%, According to Certain Wall Street Analysts was originally published by The Motley Fool Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
2 hours ago
- Yahoo
Dan Ives Says Market Is 'Massively Underestimating' This AI Play, Urges Investors To Look Beyong Mag 7
Benzinga and Yahoo Finance LLC may earn commission or revenue on some items through the links below. Dan Ives' new artificial intelligence exchange-traded fund (ETF) holds securities beyond the Magnificent 7 stocks, as he believes in looking past valuations for investments in the technology sector. What Happened: The Dan IVES Wedbush AI Revolution ETF (NYSE:IVES), managed by the Wedbush analyst, started trading on June 4, earlier this month. Ives boasts of the fund by saying that it just doesn't have the top four, five Magnificent 7 names, but stocks which investors wouldn't even thematically consider as an AI name today. "I believe the market is still massively underestimating what the growth is going to look like for the AI revolution in tech," he told CNBC. Trending: Maker of the $60,000 foldable home has 3 factory buildings, 600+ houses built, and big plans to solve housing — According to him, tech trade remains significant even for the investors who missed out on its growth in the past few years. "If you focus just on valuation, you miss every transformational tech stock of the last 20 years," Ives said. Ives says Oracle Corp. (NYSE:ORCL) will be the 'epicenter' of the AI theme, while highlighting other 'AI 30' stocks which are part of his fund. Palantir Technologies Inc. (NASDAQ:PLTR), International Business Machines Corp. (NYSE:IBM), Salesforce Inc. (NYSE:CRM), SoundHound AI Inc. (NASDAQ:SOUN), and Innodata Inc. (NASDAQ:INOD) are a few notable names that are a part of his ETF's 'AI 30' basket. Microsoft Corp. (NASDAQ:MSFT), Nvidia Corp. (NASDAQ:NVDA), and Broadcom Inc. (NASDAQ:AVGO) are the top three holdings of the IVES It Matters: The 'AI 30' stocks, which are a part of the IVES ETF, hold the AI plays from multiple industries. They include hyperscalers, cybersecurity, consumer platforms, and robotics. According to Ives, the list was compiled from his deep dives into major AI players. The ETF has $183 million in assets under management as of June 17 close. Ives said that the AI space was experiencing a "golden age." The Dan IVES Wedbush AI Revolution ETF has risen by 2.76% since its inception. A comparable index, S&P Kensho Global Artificial Intelligence Enablers, rose 6.08% on a month-to-date basis. Meanwhile, the SPDR S&P 500 ETF Trust (NYSE:SPY) and Invesco QQQ Trust ETF (NASDAQ:QQQ), which track the S&P 500 index and Nasdaq 100 index, respectively, declined slightly on Wednesday. The SPY was down 0.015% at $597.44, while the QQQ was 0.017% lower at $528.99, according to Benzinga Pro data. Read Next: Invest early in CancerVax's breakthrough tech aiming to disrupt a $231B market. Back a bold new approach to cancer treatment with high-growth potential. If there was a new fund backed by Jeff Bezos offering a 7-9% target yield with monthly dividends would you invest in it? Photo courtesy: Shutterstock This article Dan Ives Says Market Is 'Massively Underestimating' This AI Play, Urges Investors To Look Beyong Mag 7 originally appeared on
